Search research articles
Contact Us
Filters
Showing results (111-120 of 220) with videos related to
Page
of 22
Sort By:
Cancer Research
|
April 1, 1984
Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function
S J Harland, D R Newell, Z H Siddik, et al.
Current Medicinal Chemistry
|
July 14, 2012
Synthetic lethality to overcome cancer drug resistance
L Porcelli, A E Quatrale, P Mantuano, et al.
Journal of Medicinal Chemistry
|
June 12, 1992
Quinazoline antifolate thymidylate synthase inhibitors: difluoro-substituted benzene ring analogues
T J Thornton, A L Jackman, P R Marsham, et al.
Cancer Research
|
February 1, 1992
Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme
M A Graham, D R Newell, B J Foster, et al.
Journal of Environmental Quality
|
April 28, 2011
Influence of aeration implements, phosphorus fertilizers, and soil taxa on phosphorus losses from grasslands
D H Franklin, D M Butler, M L Cabrera, et al.
Molecular Pharmacology
|
February 1, 1994
A strategy for the design of membrane-permeable folypoly-gamma-glutamate synthetase inhibitors: "bay-region"-substituted 2-desamino-2-methyl-5,8-dideazafolate analogs
P C Sanghani, A Jackman, V R Evans, et al.
Cancer Research
|
September 1, 1990
Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo
A L Jackman, G A Taylor, B M O'Connor, et al.
Melanoma Research
|
April 4, 2002
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma
M J Paul, Y Summers, A H Calvert, et al.
British Journal of Cancer
|
February 1, 1991
Phase II trial of trimelamol in refractory ovarian cancer
I R Judson, A H Calvert, M E Gore, et al.
Biochimie
|
January 1, 1995
The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy
R J Griffin, N J Curtin, D R Newell, et al.
Page
of 22
Search research articles
Search
Showing results (111-120 of 220) with videos related to
Sort By:
Page
of 22
Cancer Research
|
April 1, 1984
Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function
S J Harland, D R Newell, Z H Siddik, et al.
Current Medicinal Chemistry
|
July 14, 2012
Synthetic lethality to overcome cancer drug resistance
L Porcelli, A E Quatrale, P Mantuano, et al.
Journal of Medicinal Chemistry
|
June 12, 1992
Quinazoline antifolate thymidylate synthase inhibitors: difluoro-substituted benzene ring analogues
T J Thornton, A L Jackman, P R Marsham, et al.
Cancer Research
|
February 1, 1992
Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme
M A Graham, D R Newell, B J Foster, et al.
Journal of Environmental Quality
|
April 28, 2011
Influence of aeration implements, phosphorus fertilizers, and soil taxa on phosphorus losses from grasslands
D H Franklin, D M Butler, M L Cabrera, et al.
Molecular Pharmacology
|
February 1, 1994
A strategy for the design of membrane-permeable folypoly-gamma-glutamate synthetase inhibitors: "bay-region"-substituted 2-desamino-2-methyl-5,8-dideazafolate analogs
P C Sanghani, A Jackman, V R Evans, et al.
Cancer Research
|
September 1, 1990
Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo
A L Jackman, G A Taylor, B M O'Connor, et al.
Melanoma Research
|
April 4, 2002
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma
M J Paul, Y Summers, A H Calvert, et al.
British Journal of Cancer
|
February 1, 1991
Phase II trial of trimelamol in refractory ovarian cancer
I R Judson, A H Calvert, M E Gore, et al.
Biochimie
|
January 1, 1995
The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy
R J Griffin, N J Curtin, D R Newell, et al.
Page
of 22